Coordinating Hormone Replacement Around Care Transitions: Clinical Challenges and Evidence-Based Strategies

Abstract

Transitions of care, particularly in patients requiring hormone replacement therapy (HRT), present unique challenges for clinicians due to the complexity of endocrine disorders, polypharmacy, and variable care settings. This review synthesizes recent evidence and guideline recommendations on coordinating HRT during hospital admissions, discharges, and interfacility transfers, focusing on optimizing continuity, minimizing risk, and improving outcomes in patients with adrenal insufficiency, hypothyroidism, hypogonadism, and other hormone deficiencies. Practical strategies, pathophysiological rationale, and clinical implications for healthcare professionals are discussed.

Introduction

Effective management of hormone replacement during care transitions is vital for patients with endocrine deficiencies such as adrenal insufficiency, hypothyroidism, and hypopituitarism. These patients are particularly vulnerable to adverse outcomes if their hormone replacement regimens are disrupted. With increasing healthcare complexity and frequent care transitions—between outpatient, inpatient, and long-term care settings—there is a pressing need for systematic approaches to ensure therapeutic continuity and safety. This article provides an evidence-based review of challenges, mechanisms, and best practices for coordinating HRT during care transitions for healthcare professionals.

Epidemiology / Disease Burden

Endocrine disorders requiring lifelong hormone replacement are common and increasing in prevalence. Hypothyroidism affects approximately 5% of the population in developed countries, with subclinical hypothyroidism being even more prevalent. Adrenal insufficiency, though rarer, carries significant morbidity and mortality risk if hormone therapy is interrupted, with a reported prevalence of 100–140 per million for primary adrenal insufficiency. Hypopituitarism and hypogonadism also contribute to a substantial burden of chronic disease. Care transitions—hospitalization, discharge, or transfer to rehabilitation—are frequent, particularly among older adults and those with multimorbidity, increasing the risk of medication errors and adverse outcomes related to hormone therapies.

Pathophysiology

Hormone deficiencies result from primary gland failure or secondary to hypothalamic-pituitary dysfunction. For example, primary adrenal insufficiency (Addison’s disease) leads to deficient cortisol and aldosterone, while central causes affect ACTH production. In hypothyroidism, thyroid hormone (T4) deficiency results from autoimmune destruction or secondary to pituitary dysfunction. Disrupted HRT can precipitate life-threatening adrenal crisis or myxedema coma, especially under physiological stress. The pharmacokinetics of hormone preparations—oral vs. parenteral, half-lives, and metabolic clearance—necessitate careful tailoring and monitoring during transitions. Polypharmacy, organ dysfunction, and altered absorption during acute illness further complicate management.

Risk Factors

Several risk factors predispose patients to adverse events during care transitions: polypharmacy, cognitive impairment, language barriers, lack of medication reconciliation, and absence of clear communication between healthcare settings. Patients with concomitant gastrointestinal illness, sepsis, or surgical interventions are at heightened risk due to altered absorption or increased hormone requirements. Elderly patients and those with multiple chronic conditions are especially susceptible to medication errors or omissions, underscoring the need for vigilant coordination.

Clinical Features

The clinical consequences of disrupted hormone replacement vary by endocrine disorder. In adrenal insufficiency, signs include hypotension, hyponatremia, hypoglycemia, and shock; adrenal crisis requires urgent intervention. In hypothyroidism, patients may present with lethargy, bradycardia, hypothermia, and in severe cases, myxedema coma. Hypogonadism may manifest as fatigue and mood disturbances, but acute effects of missed doses are less severe. Monitoring for symptoms and biochemical derangements is essential during transitions, especially when patients are unable to articulate their needs or symptoms.

Diagnosis

Diagnosis of hormone deficiency is based on clinical suspicion, history, and laboratory assessment—serum cortisol, ACTH, TSH, free T4, and sex hormones—often confirmed prior to chronic HRT initiation. During transitions, it is crucial to anticipate and detect incipient hormone insufficiency, particularly if dosing has been interrupted or absorption compromised. Vigilant review of medication lists, assessment of symptoms, and laboratory monitoring are cornerstones of safe transitions.

Treatment & Management

Continuity of hormone replacement is paramount. Key principles include early identification of patients on HRT at admission, prompt medication reconciliation, and ensuring timely administration of all necessary agents. For adrenal insufficiency, stress-dose steroids (e.g., hydrocortisone) should be provided perioperatively and during acute illness. Oral hormone formulations may need replacement with intravenous preparations if absorption is impaired. Discharge planning must include patient education, clear medication instructions, and communication with outpatient providers. Pharmacist involvement, transition-of-care checklists, and electronic health record alerts can enhance safety.

Recent Advances / Emerging Therapies

Recent years have seen the development of modified-release hydrocortisone and once-daily formulations for adrenal insufficiency, offering more physiological profiles and potentially reducing dosing errors during transitions. Advances in thyroid hormone analogs and delivery (e.g., liquid levothyroxine) may improve absorption in acute settings. Digital health interventions, such as electronic medication reconciliation tools and mobile health apps, are emerging to support medication continuity and patient self-management. Studies demonstrate that structured transition programs significantly reduce endocrine-related readmissions and adverse events.

Guideline Recommendations

Major guidelines from the Endocrine Society, American Thyroid Association, and international endocrine organizations emphasize the importance of uninterrupted hormone replacement during all phases of care. Recommendations include standardized protocols for steroid coverage during stress, routine medication reconciliation at transitions, and education for patients and caregivers. Multidisciplinary care teams and clear communication between hospital and outpatient providers are essential. Adherence to these recommendations demonstrably reduces morbidity, mortality, and healthcare utilization.

Conclusion

Coordinating hormone replacement during care transitions is a critical aspect of managing patients with endocrine deficiencies. Clinicians must recognize the heightened risks associated with care transitions and implement evidence-based strategies—prompt medication reconciliation, flexible dosing, patient education, and multidisciplinary communication—to ensure therapeutic continuity. Advances in formulations and digital health tools offer new opportunities for improving safety. Adherence to guideline-based protocols remains the cornerstone of optimal patient outcomes in this vulnerable population.